1. 2008 International Symposium on Pharmaceuticals in the Home PMP/TDS Update Debra Brucker, M.P.A., Ph.D. Daniel Eccher, M.P.H. Maine Office of Substance Abuse

2. PMP Overview Data collection began July 1, 2004 Data submitted by over 300 pharmacies in and out of state DEA Schedules II, III, and IV Patient-specific data directly accessible to a select few people (e.g., physicians) Intent: health care tool for reducing accessibility of controlled substances for non-medical use

3. PMP Limitations Accuracy and completeness of data up to pharmacies Many new data submitters came online in 2008 No unique identifiers; no legal ID requirement Prescriptions written for various time periods and quantities – best way to analyze unknown

4. Overall CS Counts SFY08

5. Tranquilizer Rx Counts SFY08

6. Lorazepam by Age Group Maine Patients, SFY 2008

7. Clonazepam Maine Patients, SFY 2008

8. Alprazolam Maine Patients, SFY 2008

9. Diazepam Maine Patients, SFY 2008

10. Benzodiazepine Rx Counts: Trends Maine Patients, 2004 - 2008

11. All Benzodiazepines, Maine Pts.

12. “Top 5” Benzos by Rx Count (Maine Patients, 2004 - 2008)

14. Treatment Data System (TDS) Data submitted to OSA by substance abuse treatment providers throughout Maine Government-funded programs required Some privately funded programs voluntarily submit Monthly checks on accuracy and completeness of data Comprehensive picture of SA treatment in Maine

15. Admissions to Treatment: Primary Drug = Benzodiazepine

16. Admissions to Treatment: Secondary Drug = Benzodiazepine

17. Admissions to Treatment: Tertiary Drug = Benzodiazepine

18. Treatment Admissions by Primary Drug, 1999 - 2008

19. Questions? debra.brucker@maine.gov daniel.eccher@maine.gov http://www.maine.gov/dhhs/osa/data (207) 287-2595